Actively Recruiting
Effect of Betamethasone Phonophoresis in Treatment of Vitiligo
Led by Cairo University · Updated on 2025-12-05
60
Participants Needed
1
Research Sites
1 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Vitiligo is a skin condition causing white or light patches due to loss or damage of pigment-producing cells called melanocytes. It affects up to 2% of people worldwide, across all skin types and ages. This trial evaluates the use of betamethasone phonophoresis, a method combining the steroid betamethasone with ultrasound to enhance skin absorption, aiming to improve treatment outcomes for vitiligo patients. Participants are divided into two groups. One group receives betamethasone cream followed by ultrasound application after 20 minutes, and the other group receives ultrasound first then betamethasone cream, both three times a week for one month. The ultrasound uses frequencies between 0.7 to 1.1 MHz and intensities up to 3.0 Watts per cm2, with treatment sessions lasting about 5 to 8 minutes. During the study, researchers will monitor participants for three months focusing on vitiligo management. Patients will undergo assessments to track skin pigmentation changes and treatment effects. Throughout the trial, the safety and response to the combined steroid and ultrasound treatment will be observed, with participants expected to maintain follow-up visits during the study period.
CONDITIONS
Brief Title
Betamethasone Phonophoresis For Vitiligo
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female patients diagnosed with vitiligo
- Medically and psychologically stable patients
- Good cognitive abilities to understand the requirements of the study
- Informed consent provided by all participants
- No contraindications to therapeutic ultrasound use
You will not qualify if you...
- Pregnancy or lactation
- Immunosuppression
- Alcohol abuse
- History of spontaneous re-pigmentation of lesions
- Skin characteristics interfering with study assessment
- Active bacterial or viral infection
- Use of other immune suppressants or phototherapy
- Participation in another clinical study
- Uncooperative patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 month
Participants receive betamethasone cream and ultrasound application to affected areas three times per week for 1 month to treat vitiligo.
Three visits per week for 1 month
Duration - Approximately 2 months
Participants are monitored for vitiligo management outcomes after treatment ends.
Visits as scheduled up to 3 months post treatment start
Trial Site Locations
Total: 1 location
1
Cairo University Hospital
Cairo, Egypt
Actively Recruiting
Research Team
O
Ola Sabry Abd-Elmaksoud Tarabya, MSc
N
Nisreen Afify Abd-Elrasheed, Professor
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here